• Preserving Phosphorylation States: Precision in Translationa

  2026-04-28

  Explore the mechanistic imperatives and strategic guidance for protein phosphorylation preservation in translational workflows, spotlighting APExBIO's Phosphatase Inhibitor Cocktail 1 (100X in DMSO). This article synthesizes recent findings on epigenetic regulation in oncology, benchmarks competitive solutions, and delivers actionable insights for robust phosphoproteomic analysis.

• USP36-Snail1 Axis: Ribosome Biogenesis and Solid Tumor Resis

  2026-04-28

  This study identifies the role of USP36 in stabilizing nucleolar Snail1, which enhances ribosome biogenesis and promotes cancer cell survival under ribotoxic stress. The findings clarify why ribosome inhibitors like homoharringtonine are less effective against solid tumors and suggest that targeting the JNK-USP36-Snail1 axis could improve therapeutic outcomes.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-04-27

  Oliveira et al. (2025) unveil that naturally occurring angiotensin peptides, including angiotensin III, significantly enhance binding of the SARS-CoV-2 spike protein to the host receptor AXL. This mechanistic insight links the renin-angiotensin-aldosterone system to viral entry, with implications for understanding COVID-19 pathogenesis and targeting peptide–receptor interactions in future research.

• G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt Pathway Modu

  2026-04-27

  G007-LK is a highly selective tankyrase 1/2 inhibitor with nanomolar potency. It enables precise modulation of Wnt/β-catenin signaling and induces β-catenin degradation, especially in APC-mutant colorectal cancer research models. Its efficacy and workflow parameters are well-documented and reproducible.

• Canagliflozin Alters Mitochondrial Dynamics in Diabetic Kidn

  2026-04-26

  This study demonstrates that canagliflozin, a selective SGLT2 inhibitor, promotes significant remodeling and functional enhancement of proximal tubular cell mitochondria in hypertensive–diabetic mice. These findings provide mechanistic insight into kidney protection conferred by SGLT2 inhibition, supporting its translational relevance for diabetic kidney disease research.

• ApoEVs Drive Metastasis and Stemness in Lung Adenocarcinoma

  2026-04-25

  This study elucidates how tumor-derived apoptotic extracellular vesicles (apoEVs) promote metastasis, stemness, and chemoresistance in lung adenocarcinoma by delivering ALDH1A1 and activating SOX2 transcription. The findings highlight apoEV-mediated intercellular communication as a key driver of cancer cell plasticity and suggest new avenues for therapeutic intervention and biomarker discovery.

• Indometacin Sodium in Modified Natural Cycle IVF: Efficacy a

  2026-04-24

  This article reviews a randomized controlled trial evaluating Indometacin Sodium's ability to prevent premature ovulation during modified natural-cycle IVF. While overall efficacy was limited, the study identified a patient subgroup that may benefit from prostaglandin synthesis inhibition, informing targeted reproductive protocols.

• Deferoxamine Mesylate in Ferroptosis and Tumor Resistance Re

  2026-04-24

  Explore how Deferoxamine mesylate, a leading iron-chelating agent, enables advanced modeling of ferroptosis and tumor resistance. This article uniquely connects product-specific workflows with recent breakthroughs in overcoming drug resistance in cancer research.

• Isradipine (Dynacirc): Decoding Selectivity in Calcium Chann

  2026-04-23

  Explore how Isradipine (Dynacirc) enables precise dissection of L-type calcium channel function in cardiovascular and neurodegenerative models. This article uniquely examines the pharmacological selectivity paradigm, leveraging foundational research to inform best practices in assay design.

• Trichostatin A (TSA): HDAC Inhibition for Epigenetic Researc

  2026-04-23

  Trichostatin A (TSA) is a potent, reversible HDAC inhibitor used to modulate epigenetic marks and study cell cycle regulation. It induces cell cycle arrest, differentiation, and antiproliferative effects in cancer models. TSA from APExBIO is widely applied in mechanistic oncology and epigenetic research.

• Polymyxin B Sulfate in Gram-Negative Infection & Immunity Wo

  2026-04-22

  Polymyxin B sulfate delivers precise, dual-action power for both Gram-negative infection control and immune modulation in advanced research models. This guide details hands-on protocols, troubleshooting strategies, and practical insights for maximizing its translational impact.

• Mavorixafor Hydrochloride: CXCR4 Antagonist in Precision Imm

  2026-04-22

  Explore how Mavorixafor hydrochloride, a potent CXCR4 antagonist, advances precision immunotherapy by correcting cellular migration in rare immunodeficiencies. This article delivers a scientific analysis rooted in clinical evidence and unique insights for translational research.

• HSD17B12 Regulates PD-L1 Degradation to Enhance Anti-Tumor I

  2026-04-21

  Zhou et al. (2026) reveal that the lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1, promoting cytotoxic T cell infiltration and enhancing anti-tumor immunity in mouse models. Their work uncovers a non-canonical, enzyme-independent role for HSD17B12 in immune checkpoint regulation, suggesting new therapeutic strategies for overcoming immunotherapy resistance.

• MK-1775 (Wee1 Kinase Inhibitor): Applied Workflows & Lab Ins

  2026-04-21

  Harness MK-1775 to abrogate the G2 DNA damage checkpoint and sensitize p53-deficient tumor cells with streamlined, reproducible workflows. This guide distills recent advances and hands-on troubleshooting for maximizing impact in cancer research assays.

• Tolazoline as an α2-Adrenergic Receptor Antagonist: Applied

  2026-04-20

  Tolazoline’s differentiated mechanism—α2-adrenergic receptor antagonism coupled with ATP-sensitive potassium channel modulation—empowers researchers to dissect islet and airway smooth muscle function with precision. This guide translates bench research into actionable protocols, troubleshooting tips, and comparative insights, leveraging APExBIO’s Tolazoline for robust, reproducible results.

466 records 21/32 page Previous Next First page 上5页 2122232425 下5页 Last page